Distribution of polymorphisms in MTHFR, FII G20210A, and factor V Leiden in the VITRO study
| Polymorphism . | Hyperhomocysteinemic group; n = 360 . | Normohomocysteinemic group; n = 341 . | ||
|---|---|---|---|---|
| Multivitamin; n = 177 . | Placebo; n = 183 . | Multivitamin; n = 176 . | Placebo; n = 165 . | |
| MTHFR | ||||
| cc, no. (%) | 68 (40) | 80 (47) | 92 (52) | 80 (48) |
| ct, no. (%) | 74 (44) | 70 (41) | 75 (43) | 65 (39) |
| tt, no. (%) | 28 (16) | 22 (13) | 9 (5) | 20 (12) |
| Total no. | 170 | 172 | 176 | 165 |
| FII | ||||
| gg, no. (%) | 161 (96) | 160 (95) | 166 (96) | 155 (95) |
| ga, no. (%) | 7 (4) | 9 (5) | 7 (4) | 9 (5) |
| Total no. | 168 | 169 | 173 | 164 |
| Factor V Leiden | ||||
| gg, no. (%) | 128 (81) | 139 (87) | 144 (84) | 135 (84) |
| ga, no. (%) | 30 (19) | 19 (12) | 28 (16) | 23 (14) |
| aa, no. (%) | 0 (0) | 2 (1) | 0 (0) | 3 (2) |
| Total no. | 158 | 160 | 172 | 161 |
| Polymorphism . | Hyperhomocysteinemic group; n = 360 . | Normohomocysteinemic group; n = 341 . | ||
|---|---|---|---|---|
| Multivitamin; n = 177 . | Placebo; n = 183 . | Multivitamin; n = 176 . | Placebo; n = 165 . | |
| MTHFR | ||||
| cc, no. (%) | 68 (40) | 80 (47) | 92 (52) | 80 (48) |
| ct, no. (%) | 74 (44) | 70 (41) | 75 (43) | 65 (39) |
| tt, no. (%) | 28 (16) | 22 (13) | 9 (5) | 20 (12) |
| Total no. | 170 | 172 | 176 | 165 |
| FII | ||||
| gg, no. (%) | 161 (96) | 160 (95) | 166 (96) | 155 (95) |
| ga, no. (%) | 7 (4) | 9 (5) | 7 (4) | 9 (5) |
| Total no. | 168 | 169 | 173 | 164 |
| Factor V Leiden | ||||
| gg, no. (%) | 128 (81) | 139 (87) | 144 (84) | 135 (84) |
| ga, no. (%) | 30 (19) | 19 (12) | 28 (16) | 23 (14) |
| aa, no. (%) | 0 (0) | 2 (1) | 0 (0) | 3 (2) |
| Total no. | 158 | 160 | 172 | 161 |